GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
GRAIL, Inc. filed a Form 144 disclosing a proposed sale of 9,692 common shares, acquired as restricted stock units on 04/30/2025, with an aggregate market value of $601,485.52. The filing identifies the broker as Morgan Stanley Smith Barney LLC and lists an approximate sale date of 10/02/2025 on NASDAQ. The filing also reports a recent sale by the same person of 4,202 shares on 08/19/2025 for gross proceeds of $134,548.04. The issuer's shares outstanding are listed as 36,047,799. The notice states the seller represents they possess no undisclosed material adverse information and includes the standard Rule 10b5-1 and misstatement warnings.
GRAIL, Inc. has signed a long-term lease for a new corporate headquarters at 250 S. Matilda Avenue in Sunnyvale, California. The company will lease approximately 75,556 rentable square feet from Sunnyvale Office Acquisition, LLC.
The lease is expected to begin on or about October 1, 2026 and run through on or about September 30, 2037. Initial base rent is approximately $449,558 per month, with about 5% annual increases, plus additional costs such as building expenses and taxes.
GRAIL has rights to expand into additional space and may renew the lease for an extra five-year term under specified conditions. The arrangement requires a letter of credit as security and includes customary covenants, representations, obligations and indemnities for both parties.
Joshua J. Ofman, identified as an officer (President) of GRAIL, Inc. (ticker GRAL), reported a sale of common stock on 08/19/2025. The Form 4 shows a transaction code S for the sale of 4,202 shares at a broker-calculated weighted average price of $32.02. After the sale, Ofman beneficially owned 487,874 shares on a direct basis. The filer notes the shares were sold as part of a block trade executed in multiple transactions and offers to provide detailed per-trade pricing on request. The form was signed by an attorney-in-fact on 08/20/2025.
Aaron Freidin, Chief Financial Officer and Director of GRAIL, Inc. (GRAL), reported a sale of 877 shares of GRAIL common stock on 08/19/2025 at a weighted-average price of $32.02 per share. After the reported transactions, he beneficially owns 285,143 shares, held directly. The filing states the sale was executed as a block trade in multiple transactions and that the broker-calculated price is a weighted average; the reporter offers to provide detailed per-trade pricing on request. No derivative transactions were reported.
Form 144 notice for GRAIL, Inc. (GRAL) states that an individual plans to sell 4,511 shares of the issuer's common stock on the NASDAQ with an aggregate market value of $147,964.08, against 36,047,799 shares outstanding. The securities were acquired on 06/28/2024 when 8,076 shares vested from restricted stock units issued by the company; payment was recorded as services rendered. The filer discloses two recent sales by the same person in the past three months: 9,692 shares sold on 06/12/2025 for $410,019.09 and 6,992 shares sold on 06/30/2025 for $503,984. The form includes the required representation that the seller is not aware of undisclosed material adverse information.
GRAIL, Inc. Form 144 discloses a proposed sale under Rule 144 of 952 shares of common stock by the named person, with an aggregate market value of $30,873.36, and an approximate sale date of 08/21/2025 on the NASDAQ. The shares were acquired upon vesting of restricted stock units on 06/28/2024 and were granted as compensation for services. The filing also reports a prior sale by Aaron Freidin of 8,000 shares on 07/15/2025 generating gross proceeds of $311,440. The filer affirms no undisclosed material adverse information is known.
This Schedule 13G/A reports that PRIMECAP MANAGEMENT CO/CA beneficially owns 2,057,089 shares of GRAIL common stock (class reported as COM), representing 5.72% of the outstanding class. The filing discloses sole voting power over 2,027,466 shares and sole dispositive power over 2,057,089 shares.
The statement affirms the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Items identifying group members, subsidiaries and related classifications are marked not applicable, and the filing includes the certification required under Item 10 attesting to the accuracy of the disclosure.
GRAIL, Inc. (GRAL) reported Q2 2025 results showing revenue growth and materially smaller operating losses versus prior-year periods after large pushdown impairments in 2024. Total revenue was $35.5 million for the quarter and $67.4 million for the six months, driven mainly by screening revenue. Net loss was $114.0 million for the quarter and $220.2 million for six months, versus multi‑hundred‑million and billion‑level losses in 2024 primarily from goodwill and IPR&D impairments. The balance sheet shows $130.8 million of cash and restricted cash and $475.3 million of short‑term marketable securities; management believes these resources are sufficient to fund operations for at least 12 months. The company completed its Spin‑Off from Illumina, received $932.3 million of disposal funding subject to a time‑limited clawback, and disclosed positive registrational trial signals (NHS‑Galleri prevalent round and initial PATHFINDER 2 top‑line results). Significant amortization and prior impairment charges continue to affect reported operating results and accumulated deficit.
GRAIL, Inc. furnished a press release reporting its financial results for the second quarter ended June 30, 2025; the press release is attached as Exhibit 99.1 to this current report. The 8-K text states the press release announces second-quarter financial results but does not include the underlying financial tables or metrics within the filing itself.
The exhibit is furnished, not filed, so the press release is not automatically incorporated by reference into other SEC filings unless explicitly stated. The report also identifies the company as an emerging growth company and confirms its common stock (par value $0.001) trades under the symbol GRAL on the Nasdaq Global Select Market. Readers must consult Exhibit 99.1 for the full financial figures and management commentary.